ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Evolving Concepts in ADPKD

Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the most common inherited kidney disease and the 4th leading cause of patients progressing to end-stage kidney disease (ESKD) requiring either dialysis or a kidney transplant. Despite the significant morbidity and mortality associated with ADPKD, most nephrologists are unsuspecting about its disease pathophysiology, contemporary diagnostic methods, and contemporary prognostic methods‐including tools for identifying those patients at risk for rapid progression of disease. This has led to suboptimal clinical outcomes for patients suffering from ADPKD.

During this informative session, Dr. Frederic Farid Rahbari-Oskoui, will discuss the clinical presentations of ADPKD, contemporary diagnostic and prognostic tools, PKD1 and PKD2 genotype-phenotype correlations, with illustrative cases from his own practice. Dr. Michal Mrug will explore the evolution of the concept of total kidney volume (TKV) as reflective of ADPKD disease status, and its validation as a prognostic tool for identifying patients at low, intermediate, and high risk for rapid disease progression to kidney failure. Dr. Mrug will also speak about FDA and EMA's qualification of TKV as a prognostic enrichment biomarker for selecting patients at high risk for a progressive decline in kidney function for inclusion in clinical trials.

MAT-US-2019183v1.0
Expiration Date: 3/31/2021